Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T20:00:48.073Z.
Calculation as of: 2026-10-06T20:00:48.073Z.
Quote observation: 2026-10-06T20:00:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: e8c4723d74b6f0443862f85907ca9030ea6941843cb736177163438a313e1ca1
PE RATIO
N/A
Market Cap
$138.03M
PE Ratio
N/A
TTM Avg
1879.79
3Y Avg
1257.96
5Y Avg
875.52
Market Cap
$144.66M
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alpha Cognition Inc (ACOG) | $139.47M | N/A | N/A | N/A | N/A |
| Sutro Biopharma, Inc. (STRO)vs › | $139.50M | N/A | N/A | N/A | N/A |
| Immuneering Corporation (IMRX)vs › | $138.49M | N/A | N/A | N/A | N/A |
| KORU Medical Systems, Inc. (KRMD)vs › | $138.03M | N/A | 1879.79 | 1257.96 | 875.52 |
| Nyxoah S.A. (NYXH)vs › | $142.10M | N/A | N/A | N/A | N/A |
| Organigram Global Inc. (OGI)vs › | $136.89M | 2.18 | 9.74 | 18.49 | 18.49 |
| Atrium Therapeutics, Inc. (RNA)vs › | $135.73M | N/A | N/A | N/A | N/A |
| Fortress Biotech, Inc. (FBIOP)vs › | $144.06M | 6.82 | 6.25 | 6.25 | 6.25 |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $144.66M | N/A | N/A | N/A | N/A |
| Protara Therapeutics, Inc. (TARA)vs › | $144.73M | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
